IL-10 acts to suppress inflammation resulting from both IL, interleukin; TGF-b, transforming growth factor b; TNF-a, tumor antigen-specific and innate immune responses, by reducnecrosis factor a; ULN, upper limit of normal.
is safe and well tolerated and may be clinically efficaand maintaining epithelial barrier integrity may have cious.
beneficial effects in inflammatory bowel disease. 16, 17 Finally, a preliminary clinical study has suggested that C local administration of IL-10 in cases of human ulcerative urrent medical therapy of Crohn's disease is unsatisfactory for many patients. In recent years, it has colitis may suppress mucosal inflammation. 18 become apparent that initiation and perpetuation of mu-These data from animal models and the potent anticosal inflammation is associated with a dysbalance of inflammatory properties of IL-10, resulting both from proinflammatory and anti-inflammatory cytokines prosuppression of antigen-specific T-cell activation and from duced within the intestinal mucosa. Of the proinflama direct effect on activated monocytes, suggest that this matory cytokines, tumor necrosis factor a (TNF-a) and cytokine is a candidate for therapeutic suppression of interleukin (IL)-1b have so far been identified as theramucosal inflammation in Crohn's disease. peutic targets. However, evidence now also suggests that
The present study was designed to investigate the IL-10 and transforming growth factor b (TGF-b) may safety, tolerance, and pharmacokinetics of multiple intraplay anti-inflammatory roles in the intestine. [1] [2] [3] [4] IL-10 is an 18-kilodalton cytokine produced by certain Abbreviations used in this paper: CDEIS, Crohn's disease endo-T cells, a subset of B cells, macrophages, and monocytes. objective was to look for preliminary evidence for efficacy ratio; at the two highest doses, the ratio was 3:1. The study of IL-10 treatment in this patient population.
thus provided for evaluation of 6 patients at the 0.5-, and 1.0mg/kg level (4 active drug, 2 placebo), 9 patients in the 5.0-
Materials and Methods
mg/kg dose level (6 active drug, 3 placebo), and 12 patients Patients (9 active drug, 3 placebo) in the two higher dose groups. Therefore, a total of 45 patients was included in the study. To be eligible for the study, patients had to be between Patients were screened for eligibility for a period of 14 days 18 and 65 years of age and have active steroid-resistant Crohn's to 24 hours before the first infusion. During days 09 to 03, disease involving the colon or both the ileum and colon, with patients completed daily diary entries to determine their or without external fistulae. Active steroid-resistant Crohn's CDAI. Other assessments included a complete medical history disease was defined as having a Crohn's Disease Activity Index and physical examination, chest radiography and EKG, labora-(CDAI) of ¢200 and õ350 despite treatment with prednisone tory screen and urinalysis, testing for anti-HIV, anti-HCV, at a dose ranging from 10 to 40 mg/day for more than 2
and HBsAg, and a serum pregnancy test. On day 01, an months. Prednisone could have been administered as a monoileocolonoscopy was performed. Dosing was initiated at day 1. therapy or in combination with azathioprine or 6-mercaptopu-Recombinant human IL-10 (SCH 52000, Schering Plough, rine. Either of these latter therapies had to be stable for more Kelinworth, NJ), provided as a sterile powder, was reconstituthan 6 months and were continued at a stable dose during the ted with sterile water õ1 hour before bolus injection into an study. Patients treated with other immune-modulating drugs, antecubital vein. Placebo was identical in appearance and volincluding cyclosporine, interferons, and methotrexate, were ume at each dose level. The study medication, followed by a excluded from the study. If patients had undergone such thera-10-mL saline flush, was administered at the same time of pies previously, the shortest interval between the last dose and the day during 7 consecutive days through a heparin lock or entrance into the study was specified as follows: methotrexate, butterfly. Patients were hospitalized on days 1, 2, and 7 of 2 months; anti-TNF-a, 6 months; cyclosporine, 6 months;
infusion. The 7-day infusion period was succeeded by a 3-week azathioprine/6-mercaptopurine, 6 months; and all other imfollow-up period. Investigators, members of the study staff, mune modulators, 6 months. Patients were allowed to take and patients were blinded throughout this 4-week period to aminosalicylates and/or antibiotics, providing that the dose study drug assignment, although the treatment level assignregimens were stable before and during the study. Other excluments were known to all. The treatment each patient was sion criteria were short bowel syndrome, colostomy or ileosusing for Crohn's disease at entry was continued unchanged tomy, and isolated small bowel involvement. Patients had to during the 28-day study period. Safety evaluations included have the following laboratory parameters: hemoglobin ¢ 10.0 clinical assessments, vital signs, laboratory parameters, EKG, g/dL, thrombocytes ¢ 100,000 and°800,000/mL, white radiography, and assessment of anti-IL-10 antibody formablood cells ¢ 4000/mL, granulocyte count ¢ 2000/mL, total tion. IL-10 pharmacokinetics were assessed on days 1 and 7 serum bilirubin°1.5 times the upper limit of normal (ULN), of treatment. serum creatinine°2.0 times ULN, alanine aminotransferase/ All patients were to be evaluated for adverse events during aspartate aminotransferase°2.5 times ULN, alkaline phosthe course of the study by nondirect questioning at each visit. phatase°2.5 times ULN, and INR°1.5. Women of child-An adverse event was defined as any adverse change in the bearing age might were allowed to begin infusion within 24 patient's baseline condition, which occurred during the course hours of a negative b human chorionic gonadotropin pregnancy of the study, regardless of whether the event was related to test and were required to practice adequate birth control (either treatment. Each adverse event was graded to be mild, moderoral contraception or intrauterine devices with the use of a ate, severe, or life-threatening. Clinical responses were defined barrier method) for the duration of the study. Exclusion criteria as follows: (1) a complete clinical remission was a reduction included immediate need for surgery, known severe stenosis, of the CDAI to õ150 and a decrease of the CDAI ¢ 100 prior treatment with anti-CD4 or anti-CD5 antibodies, a clinipoints, and (2) a clinical response involved a decrease of the cally abnormal chest radiograph or electrocardiogram (EKG), CDAI by ú 100 points. All other changes in CDAI were alcohol abuse, a positive test for anti-hepatitis C virus (HCV), recorded as no change. hepatitis B surface antigen (HBsAg), or anti-human immuno-
The Crohn's disease endoscopic index of severity (CDEIS) deficiency virus (HIV), a history of thrombotic events or emwas calculated on the basis of ileocolonoscopy performed at boli, and presence or history of cancer.
days 01 and 28. 19 In addition, a sigmoidoscopy was performed at day 7. To minimize interobserver variability, guidelines
Study Design
were provided to all investigators. The study was randomized, double-blind, placebo-con-Detection of IL-10 trolled, and increasing multiple dose in nature. One of five doses (0.5, 1.0, 5, 10, and 25 mg/kg body wt) of recombinant IL-10 serum concentrations were evaluated using a validated enzyme-linked immunosorbent assay (ELISA) with a human IL-10 (SCH 52000) was administered once daily by / 5e1f$$0044 07-09-97 16:29:29 gasa WBS-Gastro detection limit of 0.1 ng/mL. Anti-IL-10 antibodies were 
Results
Steroids and azathioprine/6-MP 2 (6) 3 (23) Patients were enrolled at 14 sites (3 from the ism and was withdrawn at the discretion of the investigator before dosing. The remaining 46 patients were randomized (33 to IL-10 treatment and 13 to placebo The mean steroid dose at entry into the study was 16 treatment) and began the study. One patient who had mg/day in the IL-10-treated group and 20 mg/day in been assigned to placebo treatment mistakenly received the placebo group. Steroid dosage remained unchanged a single dose (10 mg/kg) of IL-10 and was withdrawn throughout the 28-day study period. from the study. This patient's information is included
The baseline CDEIS in the IL-10 and placebo groups in the safety and adverse events listings but excluded was 15 and 14, respectively, and the proportion of pafrom efficacy analyses. With the exception of the patient tients with deep ulceration was comparable between the who received the wrong medication, all patients received treatment groups. the full week of study medications. One patient on placebo discontinued the study during week 3 of the follow-Adverse Events up period as a result of worsening of abdominal pain considered by the investigator to be unrelated to treat-Clinical adverse events were reported by almost all IL-10-and placebo-treated patients ( Table 2 ). Other ment. Patient baseline characteristics were not different between the placebo group and the IL-10-treated pa-frequently reported events were increases of white blood cell counts and gastrointestinal events. The incidence of tients. Those characteristics are presented in Table 1 . The median duration of Crohn's disease was 9 years; 30 specific adverse events was comparable among the treatment groups, although the incidence of abdominal pain of 45 patients had combined ileocolonic disease, 10 of 45 had external fistulae, and 23 of 45 had a history of was lower in the IL-10-treated group (9% vs. 31%). Most adverse events occurring during the study period bowel resection. The therapies in use for Crohn's disease were also similar in the two treatment groups (Table 1) .
were rated as mild to moderate. Six of the 33 patients / 5e1f$$0044 07-09-97 16:29:29 gasa WBS-Gastro (18%) who received IL-10 and 4 of 13 patients (31%) in phils. No apparent pattern or dose relationship was identified, and no evidence for renal or hepatic toxicity was the placebo group reported severe adverse events. Severe adverse events experienced by 2 patients who received observed. IL-10 were considered to be possibly related to treatment.
Clinical Responses One of those patients (10-mg/kg dose) developed a peri-Stringent criteria were used for the definition of anal abscess and fistula at the end of 2 weeks of followremission (decrease of baseline CDAI õ 150 and a deup. Another patient (25 mg/kg of IL-10) developed neucrease of the CDAI ú 100) and clinical response (decrease trophilia during the 7-day treatment period without of baseline CDAI ú 100). The mean CDAI decreased in symptoms of infection. In addition, 1 placebo-treated both treatment groups, but the mean CDAI scores obpatient developed a severe adverse event (pulmonary emserved during the follow-up period were generally lower bolism) at the end of 2 weeks of follow-up.
in the IL-10-treated patients (179 vs. 226 at the end of Significant shifts in laboratory results were observed the study; Figure 1 ). No apparent dose-effect relationship in both IL-10-treated (23 of 33; 70%) and placebowas observed, but it should be noted that the small treated (11 of 13; 85%) patients. Most commonly, these number of patients in each dose group precluded a meanshifts involved an increase in total or segmented neutroingful analysis. The decrease in CDAI scores was sustained throughout the 3-week follow-up period for most of the patients. The number of patients who experienced been influenced by disease activity and steroid use. The pharmacokinetic profile for IL-10 was similar to that observed in healthy volunteers and indicates that IL-10 a remission in the IL-10 group was 50% (16 of 32) and is rapidly removed from the body, without evidence for 23% (3 of 13) in the placebo group. Clinical responses accumulation after repeated administration. Disease-aswere observed in 31% of IL-10-treated patients and sociated parameters and/or concomitant drug therapy did 23% of placebo-treated individuals (Figure 2 ). Of the not appear to have any effect on the pharmacokinetic patients treated with placebo, 54% had no change in profile of IL-10. disease activity. Only 19% of IL-10-treated patients
This study was not designed to assess the efficacy of experienced no change. In most patients for whom a IL-10 treatment in Crohn's disease or to show significant complete clinical remission was obtained, the response differences in clinical responses between the treatment was usually sustained throughout the study period (Figgroups . However, 81% of IL-10-treated patients experiure 3). No potentially significant trends were observed enced either a complete clinical remission or a clinical for differences in CDEIS between the dose groups. The response, whereas only 46% of placebo-treated patients mean change was 03 (range, 013 to 5) in the IL-10had such a response. The 23% rate of clinical remissions treated patients and 04 (range, 016 to 10) in the placebo in placebo-treated patients with steroid-refractory group. A tabulation of CDEIS and CDAI failed to reveal Crohn's disease is similar to that reported in previous a correlation (data not shown).
studies and may reflect a response to hospital admission Pharmacokinetics and Anti-IL-10 and a general increase in intensity of medical care as a Antibodies consequence of participation in the clinical study. Endoscopic findings for IL-10-and placebo-treated patients Both the maximum serum IL-10 concentration and area under serum concentration time curve increased in a dose-related manner after the administration of IL- This is the first study to report on the effects of Crohn's disease is safe and generally well tolerated. The / 5e1f$$0044 07-09-97 16:29:29 gasa WBS-Gastro abrogated in experimental coltis and restored by treatment with did not reveal striking differences, and, as has been re- response was observed. It should be noted that the dose-5. Fiorentino DF, Zlotnik A, Viera P, Mosmann TR, Howard M, Moore escalating design was chosen primarily to assess safety KW, O'Garra A. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991;146:3444-3451.
and tolerance and that the number of patients in each 
